Gregory D. Perry's most recent trade in Kala Pharmaceuticals Inc was a trade of 5,450 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2025 | 5,450 | 5,450 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2025 | 2,450 | 13,344 (0%) | 0% | 0 | Common Stock | |
| Merus N.V | Gregory D. Perry | Chief Financial Officer & PFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 100,000 | 100,000 | - | - | Share Option (right to buy) | |
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 10,894 (0%) | 0% | 0 | Common Stock | |
| Merus N.V | Gregory D. Perry | Chief Financial Officer & PFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 107,300 | 107,300 | - | - | Share Option (right to buy) | |
| Merus N.V | Gregory D. Perry | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 372,924 | 372,924 | - | - | Share option (right to buy | |
| Merus N.V | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,414 | 14,414 | - | - | Share option (right to buy) | |
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Merus N.V | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 16,604 | 16,604 | - | - | Share option (right to buy) | |
| Finch Therapeutics Group Inc | Gregory D. Perry | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Merus N.V | Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 6,120 | 6,120 | - | - | Share option (right to buy) | |
| Finch Therapeutics Group Inc | Gregory D. Perry | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 55,386 | 55,386 | - | - | Employee Stock Option (right to buy) |